Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study.
Breast cancer
C-reactive protein
Cancer-related cognitive impairment
Cytokines
Journal
Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353
Informations de publication
Date de publication:
05 Jun 2024
05 Jun 2024
Historique:
received:
01
02
2024
accepted:
27
05
2024
medline:
6
6
2024
pubmed:
6
6
2024
entrez:
5
6
2024
Statut:
epublish
Résumé
Inflammation could be related to cancer-related cognitive impairment (CRCI) and might be used as a predictive marker of long-term CRCI. We evaluated associations between inflammatory markers assessed at diagnosis of breast cancer and CRCI two years afterwards. Newly diagnosed stage I-III patients with breast cancer from the French CANTO-Cog (Cognitive sub-study of CANTO, NCT01993498) were included at diagnosis (baseline). Serum inflammatory markers (IL-2, IL-4, IL-6, IL-8, IL-10, TNFα, CRP) were assessed at baseline. Outcomes at year 2 post-baseline included overall cognitive impairment (≥ 2 impaired domains) and the following domains: episodic memory, working memory, attention, processing speed, and executive functions. Multivariable logistic regression models evaluated associations between markers and outcomes, controlling for age, education, and baseline cognitive impairment. Among 200 patients, the mean age was 54 ± 11 years, with 127 (64%) receiving chemotherapy. Fifty-three (27%) patients had overall cognitive impairment at both timepoints. Overall cognitive impairment at year 2 was associated with high (> 3 mg/L) baseline CRP (OR = 2.84, 95%CI: 1.06-7.64, p = 0.037). In addition, associations were found between high CRP and processing speed impairment (OR = 2.47, 95%CI:1.05-5.87, p = 0.039), and between high IL-6 and episodic memory impairment (OR = 5.50, 95%CI:1.43-36.6, p = 0.010). In this cohort, high levels of CRP and IL-6 assessed at diagnosis were associated with overall CRCI, processing speed and episodic memory impairments two years later. These findings suggest a potential inflammatory basis for long-term CRCI. CRP may represent an easily measurable marker in clinical settings and be potentially used to screen patients at greater risk of persistent CRCI.
Sections du résumé
BACKGROUND
BACKGROUND
Inflammation could be related to cancer-related cognitive impairment (CRCI) and might be used as a predictive marker of long-term CRCI. We evaluated associations between inflammatory markers assessed at diagnosis of breast cancer and CRCI two years afterwards.
METHODS
METHODS
Newly diagnosed stage I-III patients with breast cancer from the French CANTO-Cog (Cognitive sub-study of CANTO, NCT01993498) were included at diagnosis (baseline). Serum inflammatory markers (IL-2, IL-4, IL-6, IL-8, IL-10, TNFα, CRP) were assessed at baseline. Outcomes at year 2 post-baseline included overall cognitive impairment (≥ 2 impaired domains) and the following domains: episodic memory, working memory, attention, processing speed, and executive functions. Multivariable logistic regression models evaluated associations between markers and outcomes, controlling for age, education, and baseline cognitive impairment.
RESULTS
RESULTS
Among 200 patients, the mean age was 54 ± 11 years, with 127 (64%) receiving chemotherapy. Fifty-three (27%) patients had overall cognitive impairment at both timepoints. Overall cognitive impairment at year 2 was associated with high (> 3 mg/L) baseline CRP (OR = 2.84, 95%CI: 1.06-7.64, p = 0.037). In addition, associations were found between high CRP and processing speed impairment (OR = 2.47, 95%CI:1.05-5.87, p = 0.039), and between high IL-6 and episodic memory impairment (OR = 5.50, 95%CI:1.43-36.6, p = 0.010).
CONCLUSIONS
CONCLUSIONS
In this cohort, high levels of CRP and IL-6 assessed at diagnosis were associated with overall CRCI, processing speed and episodic memory impairments two years later. These findings suggest a potential inflammatory basis for long-term CRCI. CRP may represent an easily measurable marker in clinical settings and be potentially used to screen patients at greater risk of persistent CRCI.
Identifiants
pubmed: 38840166
doi: 10.1186/s13058-024-01850-5
pii: 10.1186/s13058-024-01850-5
doi:
Substances chimiques
Biomarkers
0
C-Reactive Protein
9007-41-4
Cytokines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
93Informations de copyright
© 2024. The Author(s).
Références
Lange M, Licaj I, Clarisse B, Humbert X, Grellard JM, Tron L, et al. Cognitive complaints in cancer survivors and expectations for support: results from a web–based survey. Cancer Med. 2019;8(5):2654–63.
pubmed: 30884207
pmcid: 6536919
doi: 10.1002/cam4.2069
Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol. 2019;30(12):1925–40.
pubmed: 31617564
doi: 10.1093/annonc/mdz410
Janelsins MC, Heckler CE, Peppone LJ, Ahles TA, Mohile SG, Mustian KM, et al. Longitudinal trajectory and characterization of cancer-related cognitive impairment in a nationwide cohort study. J Clin Oncol. 2018;36(32):3231–9.
pmcid: 6225503
doi: 10.1200/JCO.2018.78.6624
Lange M, Hardy-Léger I, Licaj I, Pistilli B, Rigal O, Le Fel J, et al. Cognitive impairment in patients with breast cancer before surgery: results from a CANTO cohort subgroup. Cancer Epidemiol Biomark Prev. 2020;29(9):1759–66.
doi: 10.1158/1055-9965.EPI-20-0346
Koppelmans V, Breteler MMB, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;30(10):1080–6.
pubmed: 22370315
doi: 10.1200/JCO.2011.37.0189
Lange M, Arbogast SL, Hardy-Léger I, Rigal O, Le Fel J, Pistilli B, et al. Cognitive change in breast cancer patients up to 2 years after diagnosis. JNCI J Nat Cancer Inst. 2022;115:322–31.
doi: 10.1093/jnci/djac240
Oppegaard KR, Armstrong TS, Anguera JA, Kober KM, Kelly DL, Laister RC, et al. Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: a scoping review. Crit Rev Oncol Hematol déc. 2022;180:103822.
doi: 10.1016/j.critrevonc.2022.103822
Schroyen G, Vissers J, Smeets A, Gillebert CR, Lemiere J, Sunaert S, et al. Blood and neuroimaging biomarkers of cognitive sequelae in breast cancer patients throughout chemotherapy: a systematic review. Transl Oncol. 2022;16:101297.
pubmed: 34896851
doi: 10.1016/j.tranon.2021.101297
Van Der Willik KD, Koppelmans V, Hauptmann M, Compter A, Ikram MA, Schagen SB. Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: A cohort study. Breast Cancer Res. 2018;20(1):1–10.
Mandelblatt JS, Small BJ, Zhou X, Nakamura ZM, Cohen HJ, Ahles TA, et al. Plasma levels of interleukin-6 mediate neurocognitive performance in older breast cancer survivors: the thinking and living with cancer study. Cancer. 2023;129(15):2409–21.
pubmed: 37096888
doi: 10.1002/cncr.34784
Janelsins MC, Lei L, Netherby-Winslow C, Kleckner AS, Kerns S, Gilmore N, et al. Relationships between cytokines and cognitive function from pre- to post-chemotherapy in patients with breast cancer. J Neuroimmunol. 2022;362:577769.
pubmed: 34871864
doi: 10.1016/j.jneuroim.2021.577769
Ren X, St. Clair DK, Butterfield DA. Dysregulation of cytokine mediated chemotherapy induced cognitive impairment. Pharmacol Res. 2017;117:267–73.
pubmed: 28063894
doi: 10.1016/j.phrs.2017.01.001
Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, et al. Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study†. Annal Oncol. 2015;26(7):1446–51.
doi: 10.1093/annonc/mdv206
Toh YL, Wang C, Ho HK, Chan A. Distinct cytokine profiles across trajectories of self-perceived cognitive impairment among early-stage breast cancer survivors. J Neuroimmunol. 2020;342:577196.
pubmed: 32146169
doi: 10.1016/j.jneuroim.2020.577196
Tegeler C, O’Sullivan JL, Bucholtz N, Goldeck D, Pawelec G, Steinhagen-Thiessen E, et al. The inflammatory markers CRP, IL-6, and IL-10 are associated with cognitive function—data from the Berlin Aging Study II. Neurobiol Aging. 2016;38:112–7.
pubmed: 26827649
doi: 10.1016/j.neurobiolaging.2015.10.039
Belcher EK, Culakova E, Gilmore NJ, Hardy SJ, Kleckner AS, Kleckner IR, et al. Inflammation, attention, and processing speed in patients with breast cancer before and after chemotherapy. JNCI J Nat Cancer Inst. 2022;114(5):712–21.
pubmed: 35134984
doi: 10.1093/jnci/djac022
Carroll JE, Nakamura ZM, Small BJ, Zhou X, Cohen HJ, Ahles TA, et al. Elevated C-reactive protein and subsequent patient-reported cognitive problems in older breast cancer survivors: the thinking and living with cancer study. J Clin Oncol. 2022;41:295–306.
pubmed: 36179271
pmcid: 9839283
doi: 10.1200/JCO.22.00406
Vaz-Luis I, Cottu P, Mesleard C, Martin AL, Dumas A, Dauchy S, et al. UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO). ESMO Open. 2019;4(5):e000562.
pubmed: 31555487
pmcid: 6735667
doi: 10.1136/esmoopen-2019-000562
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.
pubmed: 1202204
doi: 10.1016/0022-3956(75)90026-6
Benedict RH, Schretlen D, Groninger L, Brandt J. Hopkins verbal learning test–revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol. 1998;12(1):43–55.
doi: 10.1076/clin.12.1.43.1726
Brickenkamp R, Zillmer E. The d2 Test of Attention. Seattle, WA: Hogrefe and Huber Publishers; 1998.
Cardebat D, Doyon B, Puel M, Goulet P, Joanette Y. Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg. 1990;90(4):207–17.
pubmed: 2124031
Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Motor Skills. 1958;8(3):271–6.
doi: 10.2466/pms.1958.8.3.271
Stroop J. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18(6):643.
doi: 10.1037/h0054651
Wechsler D. WMS-III: Wechsler memory scale administration and scoring manual. Psychological Corporation. San Antonio, TX: Psychological Corporation. 1997.
Wefel JS, Vardy J, Ahles T, Schagen SB. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703–8.
pubmed: 21354373
doi: 10.1016/S1470-2045(10)70294-1
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.
pubmed: 6880820
doi: 10.1111/j.1600-0447.1983.tb09716.x
Weis J, Tomaszewski KA, Hammerlid E, Ignacio Arraras J, Conroy T, Lanceley A, et al. International psychometric validation of an EORTC quality of life module measuring cancer related fatigue (EORTC QLQ-FA12). JNCI J Nat Cancer Inst. 2017. https://doi.org/10.1093/jnci/djw273 .
doi: 10.1093/jnci/djw273
pubmed: 28376231
Lyon DE, Cohen R, Chen H, Kelly DL, McCain NL, Starkweather A, et al. Relationship of systemic cytokine concentrations to cognitive function over two years in women with early stage breast cancer. J Neuroimmunol. 2016;301:74–82.
pubmed: 27890459
pmcid: 5181109
doi: 10.1016/j.jneuroim.2016.11.002
Kesler SR, Janelsins M, Koovakkattu D, Palesh O, Mustian K, Morrow G, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun. 2013;30(SUPPL.):S109–16.
pubmed: 22698992
doi: 10.1016/j.bbi.2012.05.017
Henneghan AM, Palesh O, Harrison M, Kesler SR. Identifying cytokine predictors of cognitive functioning in breast cancer survivors up to 10 years post chemotherapy using machine learning. J Neuroimmunol. 2018;320:38–47.
pubmed: 29759139
pmcid: 6030687
doi: 10.1016/j.jneuroim.2018.04.012
Shibayama O, Yoshiuchi K, Inagaki M, Matsuoka Y, Yoshikawa E, Sugawara Y, et al. Long-term influence of adjuvant breast radiotherapy on cognitive function in breast cancer patients treated with conservation therapy. Int J Clin Oncol. 2019;24(1):68–77.
pubmed: 30168090
doi: 10.1007/s10147-018-1330-3
Vardy JL, Stouten-Kemperman MM, Pond G, Booth CM, Rourke SB, Dhillon HM, et al. A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. Brain Imaging Behav. 2017;13(1):15–26.
doi: 10.1007/s11682-017-9728-5
Henneghan A, Wright ML, Bourne G, Sales AC. A cross-sectional exploration of cytokine-symptom networks in breast cancer survivors using network analysis. Can J Nurs Res. 2021;55(3):303–15.
doi: 10.1177/0844562120927535
Shibayama O, Yoshiuchi K, Inagaki M, Matsuoka Y, Yoshikawa E, Sugawara Y, et al. Association between adjuvant regional radiotherapy and cognitive function in breast cancer patients treated with conservation therapy. Cancer Med. 2014;3(3):702–9.
pubmed: 24756915
pmcid: 4101762
doi: 10.1002/cam4.174
Janelsins MC, Mustian KM, Palesh OG, Mohile SG, Peppone LJ, Sprod LK, et al. Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research. Support Care Cancer avr. 2012;20(4):831–9.
doi: 10.1007/s00520-011-1158-0
Amidi A, Agerbæk M, Wu LM, Pedersen AD, Mehlsen M, Clausen CR, et al. Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment. Brain Imaging Behav. 2017;11(3):769–83.
pubmed: 27240852
doi: 10.1007/s11682-016-9552-3
Henry NL, Pchejetski D, A’Hern R, Nguyen AT, Charles P, Waxman J, et al. Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case–control study. Br J Cancer. 2010;103(3):291–6.
pubmed: 20606683
pmcid: 2920022
doi: 10.1038/sj.bjc.6605768
Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol. 2005;4(6):371–80.
pubmed: 15907742
doi: 10.1016/S1474-4422(05)70099-5
Hsu PF, Pan WH, Yip BS, Chen RCY, Cheng HM, Chuang SY. C-reactive protein predicts incidence of dementia in an elderly Asian community cohort. J Am Med Dir Assoc. 2017;18(3):277.e7-277.e11.
pubmed: 28159467
doi: 10.1016/j.jamda.2016.12.006
Yang J, Fan C, Pan L, Xie M, He Q, Li D, et al. C-reactive protein plays a marginal role in cognitive decline: a systematic review and meta-analysis. Int J Geriatr Psychiatry. 2015;30(2):156–65.
pubmed: 25475551
doi: 10.1002/gps.4236
Starkweather A, Kelly DL, Thacker L, Wright ML, Jackson-Cook CK, Lyon DE. Relationships among psychoneurological symptoms and levels of C-reactive protein over 2 years in women with early-stage breast cancer. Support Care Cancer. 2017;25(1):167–76.
pubmed: 27599815
doi: 10.1007/s00520-016-3400-2
Braida D, Sacerdote P, Panerai AE, Bianchi M, Aloisi AM, Iosuè S, et al. Cognitive function in young and adult IL (interleukin)-6 deficient mice. Behav Brain Res. 2004;153(2):423–9.
pubmed: 15265638
doi: 10.1016/j.bbr.2003.12.018
Lykhmus O, Kalashnyk O, Koval L, Voytenko L, Uspenska K, Komisarenko S, et al. Mesenchymal stem cells or interleukin-6 improve episodic memory of mice lacking α7 nicotinic acetylcholine receptors. Neuroscience. 2019;413:31–44.
pubmed: 31202708
doi: 10.1016/j.neuroscience.2019.06.004
Harrell ER, Bui C, Newman SD. Alzheimer’s Disease Neuroimaging Initiative (ADNI). A mixed-effects model of associations between interleukin-6 and hippocampal volume. J Gerontol Ser A. 2022;77(4):683–8.
doi: 10.1093/gerona/glab313
Lyra e Silva NM, Gonçalves RA, Pascoal TA, Lima-Filho RAS, de Resende EPF, Vieira ELM, et al. Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer’s disease. Transl Psychiatry. 2021;11(1):1–15.
doi: 10.1038/s41398-021-01349-z
Zhao J, Zuo H, Ding K, Zhang X, Bi Z, Cheng H. Changes in plasma IL-1β, TNF-α and IL-4 levels are involved in chemotherapy-related cognitive impairment in early-stage breast cancer patients. Am J Trans Res. 2020;12(6):3046.
Williams AM, Shah R, Shayne M, Huston A, Krebs M, Murray N, et al. Associations between inflammatory markers and cognitive function in breast cancer patients receiving chemotherapy. J Neuroimmunol. 2018;314:17–23.
pubmed: 29128118
doi: 10.1016/j.jneuroim.2017.10.005
Pertl MM, Hevey D, Boyle NT, Hughes MM, Collier S, O’Dwyer AM, et al. C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy. Brain Behav Immun. 2013;1(34):108–19.
doi: 10.1016/j.bbi.2013.07.177
Bennett B, Goldstein D, Lloyd A, Davenport T, Hickie I. Fatigue and psychological distress–exploring the relationship in women treated for breast cancer. Eur J Cancer. 2004;40(11):1689–95.
pubmed: 15251158
doi: 10.1016/j.ejca.2004.03.021
Bower JE. Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol. 2008;26(5):768–77.
pubmed: 18258985
doi: 10.1200/JCO.2007.14.3248
Pang L, Li W, Yao S, Jing Y, Yin X, Cheng H. Psychological distress is involved in CRCI in breast cancer survivors via mediating cytokine levels. Cancer Med mai. 2023;12(10):11806–15.
doi: 10.1002/cam4.5847
MAYO CLINIC LABORATORIES [Internet]. 2023. MAYO CLINIC LABORATORIES. Disponible sur: https://www.mayocliniclabs.com/test-catalog/Overview/610259
Ma C, Lin M, Gao J, Xu S, Huang L, Zhu J, et al. The impact of physical activity on blood inflammatory cytokines and neuroprotective factors in individuals with mild cognitive impairment: a systematic review and meta-analysis of randomized-controlled trials. Aging Clin Exp Res. 2022;34(7):1471–84.
pubmed: 35025094
doi: 10.1007/s40520-021-02069-6
Zheng G, Qiu P, Xia R, Lin H, Ye B, Tao J, et al. Effect of aerobic exercise on inflammatory markers in healthy middle-aged and older adults: a systematic review and meta-analysis of randomized controlled trials. Front Aging Neurosci. 2019. https://doi.org/10.3389/fnagi.2019.00098 .
doi: 10.3389/fnagi.2019.00098
pubmed: 31866854
pmcid: 6906180
Kiecolt-Glaser JK, Bennett JM, Andridge R, Peng J, Shapiro CL, Malarkey WB, et al. Yoga’s Impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2014;32(10):1040–9.
pubmed: 24470004
pmcid: 3965259
doi: 10.1200/JCO.2013.51.8860
Salerno EA, Culakova E, Kleckner AS, Heckler CE, Lin PJ, Matthews CE, et al. Physical activity patterns and relationships with cognitive function in patients with breast cancer before, during, and after chemotherapy in a prospective, nationwide study. J Clin Oncol. 2021;39(29):3283.
pubmed: 34406822
pmcid: 8500586
doi: 10.1200/JCO.20.03514
Zimmer P, Baumann FT, Oberste M, Wright P, Garthe A, Schenk A, et al. Effects of exercise interventions and physical activity behavior on cancer related cognitive impairments: a systematic review. BioMed Res Int. 2016;2016:e1820954.
doi: 10.1155/2016/1820954
Duivon M, Lange M, Binarelli G, Lefel J, Hardy-Léger I, Kiasuwa-Mbengi R, et al. Improve the management of cancer-related cognitive impairment in clinical settings: a European Delphi study. J Cancer Surviv. 2023;27:2077.